Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/NATCOPHARM stock hub

NSE/NATCOPHARM has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/NATCOPHARMis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

210.4B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/NATCOPHARM

In the news

Latest news · NSE/NATCOPHARM

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E24.7

P25 24.9P50 32.4P75 45.7

Trailing P/E13.5

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC23.5

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/NATCOPHARM market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

203

Groups with data

Currency

INR

Showing 203 of 203 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	4,199
Employees Change	183%
Employees Change Percent	4.56
Enterprise value	INR 181B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE987B01026
Last refreshed	2026-05-10
Market cap	INR 210.4B
Price	INR 1,175
Price currency	INR
Rev Per Employee	10,865,920.46x
Sector	Healthcare
Sic	2834
Symbol	nse/NATCOPHARM
Website	https://www.natcopharma.co.in

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.4%
EV Earnings	11.62x
EV/EBIT	11.18x
EV/EBITDA	10.06x
EV/Sales	3.97x
Forward P/E	24.72x
P/B ratio	2.43x
P/E ratio	13.51x
P/S ratio	4.61x
PE Ratio10 Y	26.87x
PE Ratio3 Y	11.94x
PE Ratio5 Y	25.85x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	35.24%
EBITDA Margin	39.11%
Gross margin	81.97%
Gross Profit	INR 37.4B
Gross Profit Growth	2.05%
Gross Profit Growth Q	31.17%
Gross Profit Growth3 Y	29.59%
Gross Profit Growth5 Y	18.52%
Net Income	INR 15.6B
Net Income Growth	-16.51%
Net Income Growth Q	13.91%
Net Income Growth Quarters	1%
Net Income Growth Years	3%
Net Income Growth3 Y	58.78%
Net Income Growth5 Y	26.43%
Pretax Margin	40.84%
Profit Margin	34.13%
Profit Per Employee	INR 3.7M
Profitable Years	21
Roa5y	9.8
Roe5y	16.95
ROIC	23.5
Roic5y	18.08

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	10.87%
Cagr15y	23.59%
Cagr1y	45.36%
Cagr20y	22.37%
Cagr3y	25.45%
Cagr5y	5.27%
Div CAGR10	14.87%
Div CAGR3	-3.13%
Div CAGR5	-4.36%
EPS Growth	-16.51
EPS Growth Q	13.86
EPS Growth Quarters	1
EPS Growth Years	3
EPS Growth3 Y	59.77
EPS Growth5 Y	26.92
Revenue Growth	6.6x
Revenue Growth Q	36.33x
Revenue Growth Quarters	1x
Revenue Growth Years	3x
Revenue Growth3 Y	23.75x
Revenue Growth5 Y	15.96x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 32B
Debt	INR 2.6B
Debt EBITDA	INR 0.15
Debt Equity	INR 0.03
Equity	INR 86.5B
Interest Coverage	55.25
Net Cash	INR 29.4B
Net Cash By Market Cap	INR 13.99
Net Cash Growth	30.54%
Net Debt EBITDA	INR -1.65
Net Debt Equity	INR -0.34
Tangible Book Value	INR 83.9B
Tangible Book Value Per Share	INR 468
WACC	5.72

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0%
Dividend Growth	-16.67%
Dividend Growth Years	0%
Dividend per share	INR 5
Dividend Years	18
Dividend Yield	0.43%
Ex Div Date	2026-02-18
Last Dividend	INR 1.5
Payout Frequency	Quarterly
Payout Ratio	5.75%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	180.56%
1Y total return	45.32%
200-day SMA	912.5
3Y total return	97.44%
50-day SMA	1,030.3
50-day SMA vs 200-day SMA	50over200
5Y total return	29.26%
All Time High	1,639
All Time High Change	-28.32%
All Time High Date	2024-09-12
All Time Low	1.72
All Time Low Change	68,208.14%
All Time Low Date	2001-07-10
ATR	37.33
Beta	0.26
Beta1y	0.28
Beta2y	0.21
Ch YTD	30.1
High	1,218
High52	1,218
High52 Date	2026-05-08
High52ch	-3.03%
Low	1,152.1
Low52	775
Low52 Date	2025-05-09
Low52ch	51.6%
Ma50ch	14.03%
Price vs 200-day SMA	28.76%
RSI	72.51
RSI Monthly	60.27
RSI Weekly	71.41
Sharpe ratio	1.03x
Sortino ratio	1.88
Total Return	0.43%
Tr YTD	30.33
Tr15y	2,297.4%
Tr1m	8.55%
Tr1w	5.41%
Tr3m	42.91%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 16.1B
Operating Income Growth	-17.91
Operating Income Growth3 Y	52.98
Operating Income Growth5 Y	24.19
Operating margin	35.24

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	83,450,717%
Shares Insiders	29.51%
Shares Institutions	10.66%
Shares Out	179,109,870
Shares Qo Q	-0.03%
Shares Yo Y	-0%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	702,281.9x
Bv Per Share	482.9
Ch10y	158.3
Ch15y	2,036.2
Ch1m	8.55
Ch1w	5.41
Ch1y	44.48
Ch20y	4,652.8
Ch3m	42.66
Ch3y	93.24
Ch5y	24.72
Ch6m	46.41
Change	1.71%
Change From Open	1.71
Close	1,155.2
Days Gap	0
Depreciation Amortization	1,765,000,000
Dollar Volume	1,571,454,597.8
Earnings Date	2026-05-26
EBIT	INR 16.1B
EBITDA	INR 17.8B
EPS	INR 86.94
F Score	1
Fiscal Year End	March
Founded	1,981
Graham Number	971.89391
Graham Upside	-17.28
Income Tax	INR 3.1B
Is Primary Listing	1
Last Earnings Date	2026-02-12
Last Report Date	2025-12-31
Last Split Date	2015-11-26
Last Split Type	Forward
Lynch Fair Value	INR 2,173
Lynch Upside	84.99
Ma150	914.9
Ma150ch	28.42%
Ma20	1,104.4
Ma20ch	6.39%
Next Earnings Date	2026-05-26
Open	1,155.2
Payment Date	2026-03-14
Position In Range	34.6
Price Date	2026-05-08
Price EBITDA	INR 11.79
Ptbv Ratio	2.51
Relative Volume	1.84x
Revenue	45,626,000,000x
Tax By Revenue	6.75x
Tax Rate	16.53%
Tr20y	5,565.35%
Tr6m	46.92%
Volume	1,337,522

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/NATCOPHARM dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.4%

$5.00 annual per share

Payout ratio

+5.8%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-4.4%

0 consecutive years of growth

Total shareholder yield

+0.4%

Next ex-dividend date: 2026-02-18

Performance

NSE/NATCOPHARM stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/NATCOPHARM?

Insider, institutional, and short-interest positioning.

Institutional ownership

+10.7%

Share of float held by funds and institutions

Insider ownership

+29.5%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.0%

Negative means the company is buying back shares.

Technical

NSE/NATCOPHARM momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

72.5

Above 70: short-term overbought

Price vs 200-day MA

+28.8%

50/200-day relationship not available

Beta (5Y)

0.26

Less volatile than the market

Sharpe ratio

1.03

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/NATCOPHARM

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/NATCOPHARM stock rating?

nse/NATCOPHARM is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/NATCOPHARM analysis?

The full report lives at /stocks/nse/NATCOPHARM/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/NATCOPHARM?

The latest report frames nse/NATCOPHARM around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/NATCOPHARM page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.